Mixed trendabove its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Oct 12 · above the Ichimoku cloud · RSI 40 · MACD below its signal
None of the 29 investors followed here reported a position in TTRX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a TTRX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 27, 2026 | Burnam Bradley EvanChief Executive Officer | Stock Gift at price 0.00 per share. | 600K | — |
| Apr 1, 2026 | Burnam Bradley EvanChief Executive Officer | Stock Gift at price 0.00 per share. | 300K | — |
| Jan 6, 2026 | Dewhurst Martin WilliamDirector | Stock Award(Grant) at price 0.00 per share. | 21.9K | — |
| Dec 11, 2025 | Chaudhary ZuraizChief Financial Officer | Purchase at price 3.50 per share. | 2.5K | $8.75K |
| Nov 23, 2025 | Golden Arthur FDirector | Purchase at price 3.44 per share. | 9.9K | $33.95K |
| Nov 20, 2025 | Golden Arthur FDirector | Purchase at price 2.87 per share. | 20.5K | $58.93K |
| Nov 20, 2025 | Chaudhary ZuraizChief Financial Officer | Purchase at price 2.61 - 3.29 per share. | 2.5K | $7.07K |
| Nov 16, 2025 | Chaudhary ZuraizChief Financial Officer | Purchase at price 3.62 per share. | 2.5K | $9.05K |
| Oct 22, 2025 | Golden Arthur FDirector | Purchase at price 4.95 per share. | 20.2K | $100.00K |
| Oct 22, 2025 | Chaudhary ZuraizChief Financial Officer | Purchase at price 4.95 per share. | 5K | $25.00K |
| Oct 22, 2025 | Chesed AbrahamUnknown | Purchase at price 4.60 per share. | 14.3K | $65.72K |
| Oct 7, 2025 | Golden Arthur FDirector | Stock Award(Grant) at price 0.00 per share. | 10K | — |
| Oct 7, 2025 | Gengos AndrewDirector | Stock Award(Grant) at price 0.00 per share. | 10K | — |
| Oct 7, 2025 | Kester Kent EdwardDirector | Stock Award(Grant) at price 0.00 per share. | 10K | — |
| Oct 7, 2025 | Ghodadra Neilesh ShaileshOfficer and Director | Stock Award(Grant) at price 0.00 per share. | 10K | — |
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California.
Buy / hold / sell counts